Nautilus Biotechnology opened early access to its Voyager single‑molecule proteomics platform by naming Baylor College of Medicine its first customer in an early access program. Baylor will use the Voyager to map full‑length protein isoforms and develop computational toolkits to better detect protein isoforms in conventional proteomics datasets. The lead sentence: Nautilus’ platform moves from field testing to external collaborations aimed at isoform‑resolved tumor proteomics. Nautilus launched Voyager after field tests at the Buck Institute and will offer integrated reagents, fluidics and ML analytics capable of iterative mapping of billions of intact proteins in a run. Baylor’s NIH‑funded project aims to pair full‑length proteoform measurements with computational methods to improve isoform detection in standard shotgun proteomics. The move signals growing demand for next‑generation proteomics in oncology biomarker discovery and target validation. Commercial rollout slated for late 2026; researchers expect data to inform resistance mechanisms, neoantigen discovery and spatial proteomics workflows.